Cardiol Therapeutics (CRDL) Depreciation & Amortization (CF) (2020 - 2026)

Cardiol Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $19476.4 for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 11.85% year-over-year to $19476.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75051.7 (down 29.27% YoY) and the FY2025 annual result came in at $73130.6, down 37.23% from the prior year.
• Depreciation & Amortization (CF) was $19476.4 for Q1 2026 at Cardiol Therapeutics, up from $18627.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $34713.7 in Q4 2024 and bottomed at $17413.2 in Q1 2025.
• A 5-year average of $25691.7 and a median of $25665.1 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) climbed 27.66% — and 2025, when it slumped 46.34%.
• Cardiol Therapeutics' Depreciation & Amortization (CF) stood at $27201.3 in 2022, then climbed by 23.27% to $33531.5 in 2023, then advanced by 3.53% to $34713.7 in 2024, then slumped by 46.34% to $18627.0 in 2025, then advanced by 4.56% to $19476.4 in 2026.
• Business Quant data shows CRDL's Depreciation & Amortization (CF) at $19476.4 in Q1 2026, $18627.0 in Q4 2025, and $18566.3 in Q3 2025.